Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 51 min ago
Peer-reviewedCC BYHuman reproduction open

Are women cryopreserving enough oocytes for fertility preservation? A probabilistic model integrating AI-based oocyte morphology and age-dependent euploidy.

5 affiliations
  1. 1Centro de Estudos em Reprodução Assistida, Instituto Sapientiae, São Paulo, Brazil.
  2. 2Equinvitro Research and Development in Reproduction, Botucatu, Brazil.
  3. 3Future Fertility, Toronto, Canada.
  4. 4Clínica Hope, São Paulo, Brazil.
  5. 5Fertility/FERTGROUP-Medicina Reprodutiva, São Paulo, Brazil.

Abstract

Study question

How many mature oocytes are biologically required to achieve at least three euploid blastocysts, by maternal age and AI-derived oocyte quality, and how does this estimate compare with real-world oocyte yields in elective fertility preservation?Summary answer

Required oocyte numbers rise steeply with advancing maternal age and decreasing AI-derived oocyte quality, and the median number cryopreserved per fertility preservation cycle falls progressively below estimated requirements, by 12- to 30-fold in women older than 40 years.What is known already

Elective oocyte cryopreservation is increasingly used to preserve future reproductive potential, but counselling typically relies on uniform age-based oocyte targets that do not account for inter-individual variability in oocyte biological competence. Although AI-based oocyte assessment has shown promise as an objective adjunct to morphological evaluation, no biologically integrated framework has been used to translate AI-derived oocyte quality into a quantitative requirement-versus-yield comparison in fertility preservation.Study design size duration

Retrospective cohort study with probabilistic modelling of blastulation and euploidy, using three datasets from a single private university-affiliated IVF centre. Model development used 13 782 mature oocytes from 1625 autologous ICSI cycles (1020 patients, 2021-2024) and 3325 biopsied embryos with conclusive PGT-A results (857 patients). External validation was performed in 1948 oocytes from 333 ovum donation cycles in 271 donors (2020-2024). Real-world application used 1647 elective fertility preservation cycles in 1100 patients between 2012 and 2024.Participants/materials setting methods

Each oocyte was scored using a commercially available artificial-intelligence image-analysis system that assigns a 0-10 oocyte quality score. Blastulation and euploidy were modelled by logistic regression with cluster-robust standard errors. The integrated probabilistic framework computed the minimum number of mature oocytes required to obtain at least three euploid blastocysts at a probability of 90% or greater, by maternal age category and tertile of AI-derived oocyte quality score. Model-derived requirements were compared with the median number of oocytes actually cryopreserved per fertility preservation cycle.Main results and the role of chance

Blastulation increased with higher AI-derived oocyte quality score (OR 1.19 per point, 95% CI 1.18-1.21; P < 0.001) and decreased with maternal age (OR 0.94 per year, 95% CI 0.93-0.96; P < 0.001); the oocyte quality effect was externally validated in donors (OR 1.11 per point, 95% CI 1.08-1.14). Euploidy declined non-linearly with age, from 68.6% (<30 years) to 19.3% (>40 years). Estimated mature-oocyte requirements ranged from 9 (95% CI 8-11) at <30 years with high AI-derived oocyte quality to 121 (104-146) at >40 years with low AI-derived oocyte quality. The median number cryopreserved per cycle decreased from 8.3 at <30 to 4.0 at >40 years and fell progressively below estimated requirements; in women older than 40 years the observed yield was 12- to 30-fold below the estimated requirement.Limitations reasons for caution

Blastulation and euploidy probabilities were derived from autologous ICSI cycles in patients with infertility-related indications; extrapolation to elective fertility preservation candidates assumes that per-oocyte biological competence, conditional on age and AI-derived quality, is transportable across populations. The probabilistic framework assumes conditional independence between blastulation and euploidy. The model estimates oocyte requirements for euploid blastocyst formation but does not directly model implantation, clinical pregnancy, or live birth.Wider implications of the findings

The divergence between observed yields and model-derived requirements is best interpreted not as a deficiency in retrieval practice but as an individualized benchmark. Integrating AI-based oocyte assessment with age-specific euploidy probabilities may support more personalized, biologically informed counselling, expectation-setting, and care planning, particularly for women considering oocyte cryopreservation after the mid-thirties.Funding

This research did not receive any specific grant from public, commercial, or not-for-profit funding agencies. Institutional support was provided by the Sapientiae Institute and FertGroup Medicina Reprodutiva.Disclosures

J.F. and P.M. are employees of Future Fertility, the developer of the artificial-intelligence oocyte-scoring system used in this study. The remaining authors declare no competing interests.Trial registration number

N/A.

Related

  1. Precision Oncofertility: Integrating Genomics, Reproductive Biomarkers, Treatment Toxicity Profiles, and Foundation Models for Fertility Preservation in Men and Women with Cancer
    International Journal of Drug Delivery TechnologyPeer-reviewedLicence not statedFull text15 citedObstetrics, gynaecology & paediatricsOpenAlex
  2. Beyond Fertility: Ethical and Psychosocial Dimensions of Fertility Preservation in Children and Adolescents
    Mira S Aridas, Kathryn Grive
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Fertility Preservation in Women with Endometriosis: Indications, Timing, Techniques, and Reproductive Outcomes
    Luca Tramontano, Jean-Marie Wenger, Roberto Marci
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Fertility preservation with successful pregnancy outcome in a young patient with endometrial cancer
    Kejia Wu, Zhidan Hong, Ling Ma
    Journal of Assisted Reproduction and GeneticsPeer-reviewedLicence not statedFull textObstetrics, gynaecology & paediatricsPMC
  5. Fertility preservation in girls and adolescents with Turner syndrome: lessons for reproductive care in differences of sex development - a mini-review
    Zofia Kolesińska, Monika Obara-Moszyńska, Marek Niedziela +1
    Frontiers in endocrinologyPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCCrossref
BibTeX
@article{braga2026women,
  title = {{Are women cryopreserving enough oocytes for fertility preservation? A probabilistic model integrating AI-based oocyte morphology and age-dependent euploidy.}},
  author = {Daniela P A F Braga and Amanda S Setti and Maite Del Collado and Jullin Fjeldstad and Parisa Mojiri and Melissa Cavagnoli and Edson Borges},
  journal = {Human reproduction open},
  year = {2026},
  month = oct,
  doi = {10.1093/hropen/hoag090},
  url = {https://europepmc.org/article/MED/42924271},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Are women cryopreserving enough oocytes for fertility preservation? A probabilistic model integrating AI-based oocyte morphology and age-dependent euploidy.
AU  - Daniela P A F Braga
AU  - Amanda S Setti
AU  - Maite Del Collado
AU  - Jullin Fjeldstad
AU  - Parisa Mojiri
AU  - Melissa Cavagnoli
AU  - Edson Borges
PY  - 2026
DA  - 2026/10/14
JO  - Human reproduction open
DO  - 10.1093/hropen/hoag090
UR  - https://europepmc.org/article/MED/42924271
AB  - Study question  How many mature oocytes are biologically required to achieve at least three euploid blastocysts, by maternal age and AI-derived oocyte quality, and how does this estimate compare with real-world oocyte yields in elective fertility preservation?Summary answer  Required oocyte numbers rise steeply with advancing maternal age and decreasing AI-derived oocyte quality, and the median number cryopreserved per fertility preservation cycle falls progressively below estimated requirements, by 12- to 30-fold in women older than 40 years.What is known already  Elective oocyte cryopreservation is increasingly used to preserve future reproductive potential, but counselling typically relies on uniform age-based oocyte targets that do not account for inter-individual variability in oocyte biological competence. Although AI-based oocyte assessment has shown promise as an objective adjunct to morphological evaluation, no biologically integrated framework has been used to translate AI-derived oocyte quality into a quantitative requirement-versus-yield comparison in fertility preservation.Study design size duration  Retrospective cohort study with probabilistic modelling of blastulation and euploidy, using three datasets from a single private university-affiliated IVF centre. Model development used 13 782 mature oocytes from 1625 autologous ICSI cycles (1020 patients, 2021-2024) and 3325 biopsied embryos with conclusive PGT-A results (857 patients). External validation was performed in 1948 oocytes from 333 ovum donation cycles in 271 donors (2020-2024). Real-world application used 1647 elective fertility preservation cycles in 1100 patients between 2012 and 2024.Participants/materials setting methods  Each oocyte was scored using a commercially available artificial-intelligence image-analysis system that assigns a 0-10 oocyte quality score. Blastulation and euploidy were modelled by logistic regression with cluster-robust standard errors. The integrated probabilistic framework computed the minimum number of mature oocytes required to obtain at least three euploid blastocysts at a probability of 90% or greater, by maternal age category and tertile of AI-derived oocyte quality score. Model-derived requirements were compared with the median number of oocytes actually cryopreserved per fertility preservation cycle.Main results and the role of chance  Blastulation increased with higher AI-derived oocyte quality score (OR 1.19 per point, 95% CI 1.18-1.21; P < 0.001) and decreased with maternal age (OR 0.94 per year, 95% CI 0.93-0.96; P < 0.001); the oocyte quality effect was externally validated in donors (OR 1.11 per point, 95% CI 1.08-1.14). Euploidy declined non-linearly with age, from 68.6% (<30 years) to 19.3% (>40 years). Estimated mature-oocyte requirements ranged from 9 (95% CI 8-11) at <30 years with high AI-derived oocyte quality to 121 (104-146) at >40 years with low AI-derived oocyte quality. The median number cryopreserved per cycle decreased from 8.3 at <30 to 4.0 at >40 years and fell progressively below estimated requirements; in women older than 40 years the observed yield was 12- to 30-fold below the estimated requirement.Limitations reasons for caution  Blastulation and euploidy probabilities were derived from autologous ICSI cycles in patients with infertility-related indications; extrapolation to elective fertility preservation candidates assumes that per-oocyte biological competence, conditional on age and AI-derived quality, is transportable across populations. The probabilistic framework assumes conditional independence between blastulation and euploidy. The model estimates oocyte requirements for euploid blastocyst formation but does not directly model implantation, clinical pregnancy, or live birth.Wider implications of the findings  The divergence between observed yields and model-derived requirements is best interpreted not as a deficiency in retrieval practice but as an individualized benchmark. Integrating AI-based oocyte assessment with age-specific euploidy probabilities may support more personalized, biologically informed counselling, expectation-setting, and care planning, particularly for women considering oocyte cryopreservation after the mid-thirties.Funding  This research did not receive any specific grant from public, commercial, or not-for-profit funding agencies. Institutional support was provided by the Sapientiae Institute and FertGroup Medicina Reprodutiva.Disclosures  J.F. and P.M. are employees of Future Fertility, the developer of the artificial-intelligence oocyte-scoring system used in this study. The remaining authors declare no competing interests.Trial registration number  N/A.
SN  - 2399-3529
ER  -